Nimg-19. Deuterium Metabolic Imaging Interrogates The Histone H3K27M Mutation And Provides An Early Readout Of Response To Therapy In Diffuse Midline Gliomas
Celine Taglang,Georgios Batsios,Suresh Udutha,Anne Marie Gillespie,Benison Lau,Sunjong Ji,Sabine Mueller,Timothy Phoenix,Sriram Venneti,Carl Koschmann,Pavithra Viswanath
DOI: https://doi.org/10.1093/neuonc/noae165.0785
2024-11-29
Neuro-Oncology
Abstract:Diffuse midline gliomas (DMGs) are lethal primary brain tumors in children that are driven by recurrent lysine 27 to methionine mutations in histone H3 (H3K27M). Radiation is standard of care and the imipridones ONC201 and ONC206 have emerged as promising therapies for DMG patients. Although magnetic resonance imaging (MRI) is the mainstay for patient management, it does not reliably assess response to therapy. Therefore, the goal of this study was to identify metabolic alterations induced by H3K27M that can be leveraged for non-invasive metabolic imaging of DMGs. Using patient-derived (BT245, SF8628, SF7761, SU-DIPG-6, DIPG7, SU-DIPG-13) and syngeneic (26-B7, 26-C2) models, we show that the H3K27M mutation upregulates glucose metabolism via glycolysis to lactate. Silencing the H3K27M mutation reduces glycolytic capacity and depletes lactate, an effect that is associated with downregulation of rate-limiting glycolytic enzymes and transporters ( SLC2A1, HK2 , PFKFB3 , PGK1, SLC16A3). Deuterium metabolic imaging (DMI) is a novel, clinical stage method of tracing glucose metabolism in vivo. Our studies show that lactate production from [6,6- 2 H]-glucose is spatially localized to tumor vs. normal brain in mice bearing intracranial BT245, SF8628 or 26-B7 xenografts at clinical magnetic field strength (3T). Lactate production from [6,6'- 2 H]-glucose is reduced in patient-derived (BT245, SF8628, SF7761) or syngeneic (26-B7) cells treated with radiation, ONC201 or ONC206. Importantly, lactate production is reduced at an early timepoint (5 days) following treatment with ONC206, when changes cannot be detected by MRI, in mice bearing intracranial BT245 or SF8628 xenografts. Collectively, our studies link the H3K27M mutation with elevated glycolysis and identify [6,6'- 2 H]-glucose as a safe, orally administered contrast agent for visualizing the metabolically active lesion and for imaging early response to therapy in DMGs in vivo . Clinical translation of our studies will provide physicians with a much-needed tool to determine whether DMG patients are responding to standard and experimental therapies under development.
oncology,clinical neurology